Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T‐cell or null cell phenotype

The histological, immunophenotypic and clinical features of 19 primary cutaneous anaplastic large cell lymphomas (cutaneous ALCL) were compared with those of 18 primary nodal anaplastic large cell lymphomas (nodal ALCL) of T‐cell or null cell type. Although cutaneous ALCL and nodal ALCL had identical morphological features, differences in surface marker expression and clinical behaviour were found. Immunophenotypical differences concerned the expression of epithelial membrane antigen (82% of the nodal ALCL were positive v. none of the cutaneous ALCL) and the cutaneous lymphocyte antigen (HECA‐452), a possible skin‐homing receptor on cutaneous T‐lymphocytes (most tumour cells in 44% of cutaneous ALCL cases were positive, whereas nodal ALCL showed expression of HECA‐452 on only few tumour cells (< 25%) in 18% of cases tested). Loss of T‐cell markers was more pronounced for nodal ALCL. Patients with cutaneous ALCL were generally older (median 61 years) than patients with nodal ALCL (median 24 years) and, in contrast to the latter group, did not show bimodal age distribution. Survival after 4 years, using lymphoma‐related death as an end‐point, differed significantly between cutaneous ALCL and nodal ALCL; 92% for cutaneous ALCL and 65% for nodal ALCL (P=0.04). The better survival of cutaneous ALCL patients could not be ascribed to differences in age, stage or initial mode of treatment. These data indicate that differences in ismmunophenotype and clinical behaviour exist between morphologically identical primary cutaneous and primary node‐based ALCL. They indicate that the primary site is an important prognostic factor in predicting the clinical outcome of ALCL.

[1]  P. V. van Diest,et al.  Noncutaneous T‐cell lymphomas recognition of a lymphoma type (large cell anaplastic) with a relatively favorable prognosis , 1993, Cancer.

[2]  M. Paulli,et al.  Primary cutaneous CD30‐positive large cell lymphoma: Definition of a new type of cutaneous lymphoma with a favorable prognosis. A European multicenter study of 47 patients , 1993, Cancer.

[3]  P. Heerde,et al.  Differential expression of the HECA‐452 antigen (cutaneous lymphocyte associated antigen, CLA) in cutaneous and non‐cutaneous T‐cell lymphomas , 1992, Histopathology.

[4]  H. Stein,et al.  Epstein-Barr virus DNA and latent gene products in Ki-1 (CD30)-positive anaplastic large cell lymphomas. , 1991, Blood.

[5]  E. Berti,et al.  Primary cutaneous pleomorphic T-cell lymphoma expressing CD30 antigen. , 1991, The American Journal of dermatopathology.

[6]  G. Pinkus,et al.  Ki‐1–positive large cell lymphomas, a heterogenous group of neoplasms. Morphologic, immunophenotypic, genotypic, and clinical features of 24 cases , 1991, Cancer.

[7]  R. Ueda,et al.  Clinicopathologic study of large cell anaplastic lymphoma (ki‐1‐positive large cell lymphoma) among the japanese , 1991, Cancer.

[8]  J. Chan,et al.  Ki-1-positive large cell lymphoma. , 1991, The American journal of surgical pathology.

[9]  S. Banerjee,et al.  Twelve cases of Ki-1 positive anaplastic large cell lymphoma of skin. , 1991, Journal of clinical pathology.

[10]  J. Greer,et al.  Long‐term survival in Ki‐1 lymphoma , 1991, Cancer.

[11]  A. Carbone,et al.  Histopathologic, immunophenotypic, and genotypic analysis of Ki‐1 anaplastic large cell lymphomas that express histiocyte‐associated antigens , 1990, Cancer.

[12]  J. Diebold,et al.  Large anaplastic cell Ki-1 positive malignant lymphoma with peculiar endocytotic vacuoles. , 1990, Pathology, research and practice.

[13]  H. Stein,et al.  Detection of HTLV-I proviral sequences in CD30-positive large cell cutaneous T-cell lymphomas. , 1990, The American journal of pathology.

[14]  P. Heerde,et al.  Cytology of Ki‐1 (CD‐30) positive large cell lymphoma , 1990, Cytopathology : official journal of the British Society for Clinical Cytology.

[15]  C. Fletcher,et al.  Sarcomatoid variant of anaplastic large-cell Ki-1 lymphoma. , 1990, The American journal of surgical pathology.

[16]  M. Kikuchi,et al.  Genotypic and immunophenotypic analysis of anaplastic large cell lymphoma (Ki-1 lymphoma). , 1990, Pathology, research and practice.

[17]  M. Piris,et al.  CD30 expression in non‐Hodgkin's lymphoma , 1990, Histopathology.

[18]  A. Chott,et al.  Ki‐1‐Positive Large Cell Lymphoma: A Clinicopathologic Study of 41 Cases , 1990, The American journal of surgical pathology.

[19]  S. Pileri,et al.  Lymphohistiocytic T‐cell lymphoma (anaplastic large cell lymphoma CD30+/Ki‐1 + with a high content of reactive histiocytes) , 1990, Histopathology.

[20]  R. Larson,et al.  Morphology in Ki‐1 (CD30)‐Positive Non Hodgkin's Lymphoma Is Correlated with Clinical Features and the Presence of a Unique Chromosomal Abnormality, t(2;5)(p23;q35) , 1990, The American journal of surgical pathology.

[21]  R. Warnke,et al.  CD30‐positive large cell lymphomas (‘Ki‐1 lymphoma’) are associated with a chromosomal translocation involving 5q35 , 1990, British journal of haematology.

[22]  C. Meijer,et al.  Prognostic significance of CD30 (Ki-1/Ber-H2) expression in primary cutaneous large-cell lymphomas of T-cell origin. A clinicopathologic and immunohistochemical study in 20 patients. , 1989, The American journal of pathology.

[23]  E. Gwi,et al.  Epithelioid haemangioma (angiolymphoid hyperplasia with eosinophilia) and Kimura's disease in Chinese , 1989, Histopathology.

[24]  H. Stein,et al.  Primary and secondary cutaneous Ki-1+ (CD30+) anaplastic large cell lymphomas. Morphologic, immunohistologic, and clinical-characteristics. , 1989, The American journal of pathology.

[25]  A. Feller,et al.  [Large cell anaplastic lymphoma in children--clinical experiences with a newly defined histologic entity]. , 1989, Klinische Pädiatrie.

[26]  C. Meijer,et al.  Immunohistochemistry in Bone Marrow Diagnosis: Value of a Panel of Monoclonal Antibodies on Routinely Processed Bone Marrow Biopsies , 1989, The American journal of surgical pathology.

[27]  K. Lennert,et al.  Updated Kiel classification for lymphomas , 1989, The Journal of pathology.

[28]  K. Lennert,et al.  Histopathology and immunohistochemistry of peripheral T cell lymphomas: a proposal for their classification. , 1987, Journal of clinical pathology.

[29]  P. Isaacson,et al.  Malignant lymphoma of mucosa‐associated lymphoid tissue , 1987, Histopathology.

[30]  K. Lennert,et al.  The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. , 1985, Blood.

[31]  A. Sonnenberg,et al.  Monoclonal antibodies against human milk‐fat globule membranes detecting differentiation antigens of the mammary gland and its tumors , 1984, International journal of cancer.

[32]  F. Dallenbach,et al.  Peripheral T-cell lymphomas. , 1991, Annals of Oncology.

[33]  L. Picker,et al.  A unique phenotype of skin-associated lymphocytes in humans. Preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. , 1990, The American journal of pathology.

[34]  F. Berger,et al.  Original article: Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen , 1990 .

[35]  A. Steere,et al.  High endothelial differentiation in human lymphoid and inflammatory tissues defined by monoclonal antibody HECA-452. , 1988, The American journal of pathology.

[36]  H. Stein,et al.  Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis. , 1988, The American journal of pathology.